top of page
Якорь 5
AdobeStock_201606402_edited.jpg
Alzheimer's Global Challenge Ecosystem

Alzheimer's is widely prevalent worldwide, posing challenges for effective treatment in clinics and leading to extensive health consequences. Alzheimer's disease is a progressive neurological disorder that primarily affects memory and cognitive functions. The symptoms can vary among individuals, but common signs of Alzheimer's disease include: Memory Loss, Confusion with Time or Place, Language and Communication Problems, Withdrawal from Social and Work Activities and etc. At Deep Knowledge Group and Longevity Industry Analytics, we recognize the severity of this disease and possess the profound expertise necessary to cure and mitigate its consequences. 

Our primary goal is to halt the spread of this widespread condition and minimize or, ideally, eliminate its long-term health implications. Thanks to our experience and analytics in this field,  in collaboration with advanced clinics and leading specialistd, we have unique capabilities to alleviate the burden of Alzheimer's. We actively invite investors and partners to collaborate with us in an advanced approach to addressing this urgent global issue. Together, we can influence the course of events and contribute to more effective management of this challenge in modern medicine.

Global Perspective

Alzheimer's disease has the profound impact  on individuals, families, and societies worldwide. With an aging global population, Alzheimer's has emerged as a significant public health challenge, transcending borders and cultural contexts. More than 50 million people have been diagnosed with this condition. Alzheimer's and other dementia is the 7th leading cause of death in the world. Understanding factors influencing Alzheimer's prevalence is crucial for effective prevention, diagnosis, and management.

The prevalence of Alzheimer's varies across regions, influenced by demographic factors, healthcare infrastructure, and awareness. Developed nations often grapple with a higher prevalence due to longer life expectancies and improved diagnostic capabilities. However, the burden is increasingly felt in developing countries as well, where aging populations are on the rise.

One of the critical global challenges is the need for heightened awareness and understanding of Alzheimer's. Stigma and misconceptions surrounding dementia persist in various cultures, hindering timely diagnosis and support for affected individuals. The global community has recognized the urgency of destigmatizing Alzheimer's and fostering a more inclusive environment for those living with the condition.

Research on Alzheimer's is a collaborative endeavor, with scientists and healthcare professionals around the world working to unravel the complexities of the disease. International cooperation and knowledge-sharing are essential for advancing our understanding of Alzheimer's risk factors, potential treatments, and preventive measures.

Policy initiatives and governmental responses vary, reflecting diverse healthcare systems and priorities. Some countries have established national strategies to address Alzheimer's, emphasizing research funding, caregiver support, and public education. Others are in the early stages of recognizing Alzheimer's as a significant public health concern, highlighting the need for a unified global response.

Percent of people with Alzheimer's

Efforts to support individuals living with Alzheimer's and their caregivers are gaining prominence globally. Advocacy groups, nonprofits, and healthcare organizations are working tirelessly to enhance support networks, raise awareness, and influence policy changes to better address the multifaceted challenges posed by Alzheimer's.

In summary, the global perspective of Alzheimer's underscores the need for a concerted and collaborative approach. From increasing awareness and research initiatives to destigmatizing the condition and improving support systems, the global community faces the challenge of addressing Alzheimer's on multiple fronts to provide better outcomes for those affected by this pervasive and complex disease.

Alzheimer's Global Challenge Ecosystem

Alzheimer's & Lyme Disease:

Exploring Connections

Persistent Borrelia cysts, causing Lyme disease, may reawaken with aging, potentially influencing Alzheimer's progression. Recent research discovered Lyme Borrelia DNA in postmortem Alzheimer's brains, suggesting a potential link between these diseases. IHHT-MITOPRO provides a practical strategy to prevent latent Lyme Borreliosis, preserving immune system effectiveness.

Understanding these potential links between Lyme disease and Alzheimer's is crucial for comprehensive health management and emphasizes the importance of early intervention strategies. Let's delve deeper into the intricate interplay between these conditions.

Снимок экрана 2024-01-20 в 16.34.41.png

Alzheimer's Global GeoDashboard

3300+

Clinic Trials 

400+

Top Clinics

3000+

Investors 

25000+ 

Data Points 

Якорь 3

Read More

Alzheimer's Market in Charts

Anticipated to undergo significant expansion, the global market for Alzheimer's Disease methods of treatment is poised to grow from USD 2.2 billion in 2021 to USD 13.7 billion in 2030, reflecting a robust Compound Annual Growth Rate (CAGR) of around 4.4%.

The upsurge in healthcare advancements, backed by substantial investments from major corporations and government institutions, underscores the increasing importance of precise diagnostics and refined treatment approaches in addressing the intricacies of Alzheimer's disease. This extends to providing comprehensive support for individuals across the entire spectrum, including those with mild forms.

Alzheimer's Disease Diagnostics Market Size, $bn

Experiencing a Compound Annual Growth Rate (CAGR) of approximately 8% during this period, the market for Alzheimer's disease diagnostic tools is on a robust trajectory. This growth is propelled by heightened awareness and reporting of Alzheimer's cases, advancements in diagnostic technologies, and sustained investments in research and development aimed at creating more precise and effective diagnostic tools.

 

Projections indicate a steady market expansion, with an anticipated rise from USD 3.3 billion in 2022 to USD 7.1 billion in 2030. This underscores the increasing demand for advanced diagnostic solutions in detecting Alzheimer's, with a focus on early identification and enhanced condition management.

Solutions for Global Health Challenges 

The Lyme Pandemia with Diabetes, Autism and Alzheimer Diseases pose a significant challenge, with a growing pharmaceutical market each year. Despite this expansion, the issue persists, highlighting the complexity and difficulty in finding a comprehensive resolution to the problem. This group of diseases are not effectively addressed solely through standard treatments.

 

At DKG, we frequently encounter people facing challenges in managing their symptoms even after undergoing conventional therapy. Drawing on over a decade of analytical expertise, we have accumulated and explored advanced holistic methods to effectively impact on the spread of these problems in the World. 

Our proficiency in treating such diseases revolves around discerning the coinfections and other complicating factors associated with these  ailment. To tackle this distinct set of considerations our specialists employ personalized proprietary treatments that integrate cutting-edge and natural therapies related to Mitochondrial, Space, Restorative, Functional Medicine within the framework of Longevity Medicine.

Снимок экрана 2024-02-08 в 20.58.07.png
Снимок экрана 2024-02-08 в 20.59.02.png
Снимок экрана 2024-02-08 в 21.00.31.png
Снимок экрана 2024-02-08 в 21.01.44.png

Alzheimer's Global Challenge Ecosystem Dashboard

The Alzheimers Global Challenge Ecosystem Dashboard is a centralized hub designed to meet all the market and business intelligence needs of its users. It offers comprehensive support, encompassing benchmarking for companies, technologies, and thorough competitive and SWOT analysis for over 12000 clinics, 3300+ clinical trials, 3000+ investors, and 25,000+ data inputs within the Alzheimer's sector.

Снимок экрана 2023-12-09 в 14.27.38.png
Screenshot Alzheimers 2.png

Alzheimer's Patient Logistic Pathway

Explore the comprehensive journey of Alzheimer's patients through the interactive Logistic Pathway. Each stage offers a concise overview, and by selecting individual stages, you can delve into detailed descriptions that provide insights into AI-driven diagnostic, treatment, and management processes tailored specifically to Alzheimer's. For more in-depth information about clinics, diagnostics, and treatments, use the Global Autism Dashboard.

Якорь 4

Teaser

Alzheimers Teaser Preview.png

One Pager

Alzheimers One-pager Preview.png

Report

Alzheimers Report Preview.png

Alzheimer's Clinical Trials

The United States stands as the primary research center for Alzheimer's clinical trials, hosting over 53% of these studies.

 

More than 5% of clinical trials are launched in France. Canada, Taiwan, UK and China have similar number of clinical trials, each around 3%. Together, European countries make more than 18% of clinical trials. In total, more than 50 countries have participated in Alzheimers clinical trials.

After 2017, the annual number of clinical trials more than doubled increasing to 134 studies per year. The jump in clinical trials after 2017 signals a rising awareness of Alzheimer's significance.

The most significant players in the market are Massachusetts General Hospital (USA), Stanford University (USA), National Taiwan University Hospital (Taiwan), Yale University (USA), University of California, Los Angeles (USA),  Children's Hospital Medical Center, Cincinnati (USA), National Institute of Mental Health (USA).

Strategic Partner Projects

lyme.png

Lyme Disease

Global Pandemia

autism.png

Autism Global

Challenge Ecosystem